Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127682881 | 12768288 | 1 | I | 201605 | 20160907 | 20160921 | 20160921 | EXP | CH-TEVA-692250ISR | TEVA | 68.00 | YR | M | Y | 69.00000 | KG | 20160922 | OT | CH | CH |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127682881 | 12768288 | 1 | PS | IBUPROFEN. | IBUPROFEN | 1 | LONG TERM TREATMENT | D | 71145 | 800 | MG | ||||||||
| 127682881 | 12768288 | 2 | SS | VIREAD | TENOFOVIR DISOPROXIL FUMARATE | 1 | Oral | 1 DOSAGE FORMS DAILY; | Y | 0 | 1 | DF | TABLET | ||||||
| 127682881 | 12768288 | 3 | SS | VIREAD | TENOFOVIR DISOPROXIL FUMARATE | 1 | Oral | 1 DOSAGE FORMS DAILY; | Y | 0 | 1 | DF | TABLET | ||||||
| 127682881 | 12768288 | 4 | SS | Moduretic Mite | AMILORIDE HYDROCHLORIDEHYDROCHLOROTHIAZIDE | 1 | Oral | 1 DOSAGE FORMS DAILY; 1 DF = 25 MG HYDROCHLOROTHIAZIDE + 2.5 MG AMILORIDE HYDROCHLORIDE | U | 0 | 1 | DF | TABLET | ||||||
| 127682881 | 12768288 | 5 | SS | ATACAND | CANDESARTAN CILEXETIL | 1 | Oral | 32 MILLIGRAM DAILY; LONG TERM TREATMENT | 0 | 32 | MG | TABLET | QD | ||||||
| 127682881 | 12768288 | 6 | C | Aspirin cardio | ASPIRIN | 1 | 25 MILLIGRAM DAILY; | 0 | 100 | MG | |||||||||
| 127682881 | 12768288 | 7 | C | Pantoprazol | PANTOPRAZOLE SODIUM | 1 | 0 | 40 | MG | ||||||||||
| 127682881 | 12768288 | 8 | C | Paracetamol | ACETAMINOPHEN | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127682881 | 12768288 | 1 | Pain |
| 127682881 | 12768288 | 2 | Chronic hepatitis B |
| 127682881 | 12768288 | 4 | Hypertension |
| 127682881 | 12768288 | 5 | Essential hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127682881 | 12768288 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127682881 | 12768288 | Asthenia | |
| 127682881 | 12768288 | Blood creatine phosphokinase increased | |
| 127682881 | 12768288 | Blood potassium increased | |
| 127682881 | 12768288 | Dyspnoea exertional | |
| 127682881 | 12768288 | Hyperlactacidaemia | |
| 127682881 | 12768288 | Muscular weakness | |
| 127682881 | 12768288 | Myalgia | |
| 127682881 | 12768288 | Renal failure | |
| 127682881 | 12768288 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127682881 | 12768288 | 2 | 20150306 | 20160725 | 0 | |
| 127682881 | 12768288 | 3 | 20160829 | 20160829 | 0 |